A groundbreaking new study conducted by researchers at Aarhus University and Aarhus University Hospital has called into question the recent precautionary guidelines issued by the European Medicines Agency (EMA) regarding the paternal use of valproate during spermatogenesis. Published in the prestigious journal JAMA Network Open on May 22, 2025, this expansive population-based cohort study, encompassing more than 1.2 million Danish children, meticulously examined whether valproate treatment in fathers influences the risk of neurodevelopmental disorders in their offspring. The findings unequivocally showed no statistically significant increase in such risks, challenging the basis of EMA’s recent warnings.
Valproate, a medication primarily used to treat epilepsy and bipolar disorder, has long been scrutinized for its teratogenic effects when used by pregnant women. However, the potential impact of paternal exposure during sperm development has remained less clear and highly contentious. In January 2024, EMA advised healthcare professionals to exercise caution when prescribing valproate to men of reproductive age, based largely on a report from IQVIA, a global contract research organization. This advisory was intended to mitigate potential risks to future children, but it has sparked vigorous debate among medical researchers and clinicians.
Critically, the Aarhus University team’s latest analysis extends beyond their initial study, which had failed to replicate the IQVIA findings but was limited by lack of detailed information on IQVIA’s methodology. In this new article, the researchers aligned their analytic strategies more closely with those of IQVIA, including definitions and exposure timing, providing for an apples-to-apples comparison. Despite this rigorous approach, their conclusion remained robust: there was no evidence supporting an elevated risk of neurodevelopmental disorders such as autism spectrum disorder or intellectual disabilities linked to paternal valproate use during spermatogenesis.
This revelation has significant implications not only for clinical practice but also for regulatory policy. Precautionary measures impacting medication use in men have profound downstream effects, influencing treatment decisions, fertility counseling, and patient counseling. Julie Werenberg Dreier, a senior researcher at the National Centre for Register-based Research at Aarhus University, emphasized that precautionary guidelines lacking strong scientific backing could engender unnecessary fear and anxiety among patients and providers. She warned that such measures must be founded on unassailable evidence to avoid impeding effective treatment options for men with neurological or psychiatric conditions.
Jakob Christensen, a consultant neurologist and professor at Aarhus University Hospital and Aarhus University, further underlined the exhaustive nature of the team’s investigations. The researchers leveraged Denmark’s comprehensive national registries, which offer unparalleled longitudinal data linking parental medication use to offspring health outcomes. This massive dataset allowed the team to construct a cohort of over 1.2 million children born between 1997 and 2017, comparing paternal valproate exposure to other antiepileptic drugs such as lamotrigine and levetiracetam. Even with these robust comparisons, no increase in neurodevelopmental risks was detected.
One of the technical strengths of this study lies in its population-based cohort design, minimizing selection bias and maximizing the generalizability of findings. Such register-based approaches are particularly valuable in epidemiological research where randomized controlled trials are not feasible. The methodology incorporated extensive covariate adjustments, including parental age, socioeconomic status, and co-morbidities. Data were extracted and analyzed using advanced statistical techniques to ensure that confounding factors did not obscure the study outcomes.
The researchers’ insistence on transparency and scientific rigor echoes through the study’s conclusions. Given the contradictory results between their work and the IQVIA report, they advocate for the public release of the IQVIA study’s analytical code and a comprehensive peer review. This call reflects a broader need in pharmacoepidemiology and regulatory science for open data practices to foster reproducibility and trust, especially when public health guidelines may affect millions.
Equally pivotal is the study’s spotlight on paternal exposures—a research domain traditionally overshadowed by maternal-focused teratology studies. By deepening our understanding of how medications taken by fathers before conception might or might not impact offspring, this work pushes the frontiers of reproductive medicine and neurodevelopmental epidemiology. It also warns against premature policy decisions based on incomplete or nontransparent studies, especially where the benefits of critical medications like valproate are well established.
This research also implicitly raises questions about the biological plausibility of paternal valproate effects during spermatogenesis. While valproate is known to cross biological barriers and affect epigenetic markers, the lack of observed clinical effects on offspring neurodevelopment suggests that either such mechanisms do not translate into measurable outcomes or that compensatory biological processes mitigate potential harms. Further mechanistic studies are warranted to elucidate these pathways.
Moreover, this study underscores the vital role of national health registries in facilitating high-quality pharmacoepidemiological research. Denmark’s integrated healthcare data infrastructure enables researchers to undertake studies encompassing millions of individuals with detailed medication and diagnosis records. Such datasets are indispensable in teasing apart subtle risks or confirming safety signals for widely used drugs, underpinning evidence-based healthcare policies.
In conclusion, the Aarhus research team’s comprehensive and methodologically rigorous investigation decisively refutes the assertion that paternal valproate treatment during sperm development elevates neurodevelopmental disorder risk in offspring. This evidence should prompt regulatory bodies like EMA to carefully reconsider precautionary measures, ensuring they are aligned with the best available science to safeguard patients without generating unwarranted alarm. The study exemplifies the power of large-scale register studies to clarify contentious clinical questions and underscores the imperative for transparency and open scientific dialogue in guiding public health decisions.
Subject of Research: Paternal exposure to valproate and its association with neurodevelopmental disorders in offspring
Article Title: The risks of neurodevelopmental disorders associated with paternal use of valproate during spermatogenesis
News Publication Date: 22-May-2025
Web References:
https://dx.doi.org/10.1001/jamanetworkopen.2025.12139
References:
Christensen J, Trabjerg BB, Dreier JW. The risks of neurodevelopmental disorders associated with paternal use of valproate during spermatogenesis. JAMA Network Open. May 22, 2025. DOI: 10.1001/jamanetworkopen.2025.12139
Keywords: Valproate, neurodevelopmental disorders, paternal exposure, spermatogenesis, epidemiology, pharmacoepidemiology, register-based cohort study, epilepsy medication, EMA precautionary measures, reproductive toxicology, data transparency, regulatory science
Tags: Aarhus University study on valproateclinical guidelines for prescribing valproatedebate on paternal exposure to medicationsEuropean Medicines Agency precautionary guidelinesimplications of paternal medication useJAMA Network Open publication on valproate.paternal valproate use and neurodevelopmental disorderspopulation-based cohort study Denmarkrisk of neurodevelopmental disorders in childrenvalproate and spermatogenesis researchvalproate teratogenic effectsvalproate treatment in fathers
